Quest Diagnostics Insider Sold Shares Worth $5.48 Million
A recent SEC filing indicates that an insider at Quest Diagnostics Incorporated sold company shares valued at approximately $5.48 million.
Stocks · News reference
Quest Diagnostics reported third-quarter 2026 financial results that exceeded analyst expectations and subsequently increased its full-year 2026 outlook.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
A recent SEC filing indicates that an insider at Quest Diagnostics Incorporated sold company shares valued at approximately $5.48 million.
DOT Consortium has launched new return-to-duty and follow-up testing packages on its online compliance platform, which integrates with Quest Diagnostics' laboratory network.
Evercore ISI has updated its price target for Quest Diagnostics, raising it from $235 to $240.
Rothschild & Co Redburn has increased its price target for Quest Diagnostics Incorporated, moving it from $251 to $279.
Quest Diagnostics disclosed a cybersecurity incident involving unauthorized access to its Quanum Lab Services Manager platform, potentially impacting patient data.
Deutsche Bank has updated its price target for Quest Diagnostics, moving it from $232 to $245 while maintaining a 'Hold' rating.